Revvity RVTY Life Sciences — Restructuring and Other Costs (Income)
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Revvity in its filing.
Tagged under the XBRL concept us-gaap:RestructuringCosts.
The official record: Revvity’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Revvity's life sciences — restructuring and other costs (income).
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Revvity's life sciences — restructuring and other costs (income)?
- Revvity (RVTY) reported life sciences — restructuring and other costs (income) of $3.23M in Q1 2026.
- How has Revvity's life sciences — restructuring and other costs (income) changed year-over-year?
- Revvity's life sciences — restructuring and other costs (income) increased by 27.7% year-over-year, from $2.53M to $3.23M.
- What does life sciences — restructuring and other costs (income) mean?
- One-time expenses related to reorganizing the Life Sciences business.
- How do you interpret life sciences — restructuring and other costs (income)?
- High costs may signal short-term disruption but often precede improved margins through cost-saving initiatives.
- How does life sciences — restructuring and other costs (income) compare across companies?
- Comparable to 'Restructuring Charges' or 'Special Items' reported by peers undergoing operational transformation.